Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
cancer  clinical  company  development  marketwired sep  marketwired september  marketwired  medical  medicine  new  sep  september 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Fri, 30 Sep 2016 15:55:23 EDT

Copyright: Copyright: (C) Marketwired
 



CVR Medical Retains Brisco Capital Investor Relations

Fri, 30 Sep 2016 14:43:46 EDT

VANCOUVER, BC--(Marketwired - Sep 30, 2016) -  CVR Medical Corp. (TSX VENTURE: CVM) ("CVR Medical") is pleased to announce that it has entered into a consulting agreement effective as of September 27, 2016 with Brisco Capital Partners Corp. ("Brisco Capital") for the provision of investor relation services. 




Cognate BioServices Announces Strategic Collaboration With Terumo BCT

Fri, 30 Sep 2016 08:30:00 EDT

HANOVER, MD--(Marketwired - Sep 30, 2016) - Cognate BioServices announced today a collaboration with Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, to support the development of cell and immunotherapy products. Cognate is a leader in current good manufacturing practices (cGMP) and provides regulatory support to companies and institutions engaged in the development of regenerative medicine and cell-based products and therapies. 




Will Your CMC Data be IDMP e-Submission Ready by 2018? New Webinar Hosted by Xtalks

Fri, 30 Sep 2016 07:00:00 EDT

TORONTO, ON--(Marketwired - September 30, 2016) - During the webinar, Maroun Elias, Business Analyst and Structured Substance Information (SSI) SME at NNIT USA will outline key findings of a customer use case that involved an SSI impact assessment for a chemical and protein substance according to the latest ISO Implementation Guideline (March 2016). The live event will take place on Wednesday, October 19, 2016 at 1pm EDT.




ANGLE PLC: Research Published in Clinical Chemistry

Fri, 30 Sep 2016 02:00:00 EDT

GUILDFORD, UNITED KINGDOM--(Marketwired - Sep 30, 2016) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)




Proove Biosciences Founder & CEO, Brian Meshkin, Set to Speak at Executive Next Practices Forum on Healthcare

Thu, 29 Sep 2016 14:09:39 EDT

Renowned Expert in the Field of Precision Medicine Joins Network of Fortune 500 C-Level Executives to Discuss Impact of Genomics on Improving Outcomes in Pain




Hamilton Thorne Extends the Term of Outstanding Debentures

Thu, 29 Sep 2016 13:51:56 EDT

BEVERLY, MA and TORONTO, ON--(Marketwired - Sep 29, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets announced today that is has reached an agreement to amend (the "Debenture Amendments") its $300,000 unsecured subordinated debentures (the "Debentures") dated August 29, 2012 to extend the maturity date of the Debentures from October 1, 2016 to October 1, 2017. All other terms and conditions of the Debentures, as amended, were ratified and confirmed.




EAG Laboratories Appoints Duane Huggett, Ph.D., as Senior Scientific Advisor for Its Environmental Testing Group

Thu, 29 Sep 2016 12:31:00 EDT

Expert in Environmental Risk Assessment, Toxicology and Pharmacology Joins Company




Governor Brown Signs Into Law the California Cancer Clinical Trials Program

Thu, 29 Sep 2016 11:00:00 EDT

New Law Will Help Increase Patient Enrollment, Retention, and Minority Participation in Cancer Clinical Trials, Especially Among Women and Under-Represented Communities




Amid 2016 Uptrend, Shares of Innovus Pharma Consolidate on Technical Support - SECFilings.com

Thu, 29 Sep 2016 10:04:29 EDT

REDONDO BEACH, CA--(Marketwired - Sep 29, 2016) -  SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article analyzing Innovus Pharmaceuticals' (OTCQB: INNV) stock chart from a technical perspective, along with a discussion of the company's fundamentals.




Clasado BioSciences to Showcase Bimuno(R) for First Time at SupplySide West

Thu, 29 Sep 2016 10:02:00 EDT

Leading Biotech Company Launches Patent Protected Galacto-Oligosaccharide Bimuno(R) (B-GOS(R)) at Prominent Industry Trade Show




Endonovo at the Intersection of Stem Cells and Biologics for Next Generation Therapeutics - SECFilings.com

Thu, 29 Sep 2016 08:58:46 EDT

REDONDO BEACH, CA--(Marketwired - Sep 29, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article covering the unique technology that Endonovo Therapeutics (OTCQB: ENDV) is applying in the development of biologics and stem cells.




iBio Proprietary Technology Advances Neonatal Respiratory Distress Syndrome Drug Development for South African Biotech Company AzarGen Biotechnologies (Pty) Ltd

Thu, 29 Sep 2016 08:30:00 EDT

NEW YORK, NY--(Marketwired - Sep 29, 2016) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products announced the successful application of its proprietary technologies to achieve the first milestone in its commercial development agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) of South Africa for the development and manufacture of an improved surfactant protein for the treatment of neonatal respiratory distress syndrome (RDS).




Critical Outcome Technologies Reports Fiscal 2017 First Quarter Financial and Operating Results

Thu, 29 Sep 2016 08:30:00 EDT

LONDON, ON and BOSTON, MA--(Marketwired - September 29, 2016) - Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") reported its financial and operating results today for the three-month period ended July 31, 2016. Major highlights for the quarter included:




MYOS RENS Announces Publication of Its Fortetropin(R) Human Clinical Trial Manuscript

Thu, 29 Sep 2016 08:00:00 EDT

Peer-Reviewed Study Published in The Journal of the American College of Nutrition Demonstrating That Fortetropin(R) Increased Lean Body Mass (LBM), Increased Muscle Thickness, and Decreased Markers of Protein Breakdown




Abeona Therapeutics to Present at Cell Gene Meeting on the Mesa

Thu, 29 Sep 2016 07:03:00 EDT

Company CEO to Present on October 5th at 11:15 am PT




RNA-Seq in Colorectal Cancer Defines Neoplastic and Stromal Features Impacting Future Treatments, New Webinar Hosted by Xtalks

Thu, 29 Sep 2016 07:00:00 EDT

TORONTO, ON--(Marketwired - September 29, 2016) - In this webinar, industry expert Dr. Enzo Medico, Associate Professor at the University of Torino, School of Medicine, Candiolo Cancer Institute will outline research studies that have been performed to exploit global transcriptional profiling of colorectal cancer samples.




Vernalis PLC Announces Results Announcement for the 12 Months Ended 30 June 2016

Thu, 29 Sep 2016 02:00:00 EDT

WINNERSH, UNITED KINGDOM--(Marketwired - Sep 29, 2016) - Vernalis PLC (LSE: VER) (OTC PINK: VNLPY)




Tiziana Life Sciences PLC Announces Interim Results for the Six Months Ended 30 June 2016

Thu, 29 Sep 2016 02:00:00 EDT

LONDON, UNTIED KINGDOM--(Marketwired - Sep 29, 2016) - Tiziana Life Sciences plc (AIM: TILS)




Avita Medical Signs Exclusive Distributor Deal in Iran

Wed, 28 Sep 2016 23:42:19 EDT

Dedicated ReNovaCell(TM) Clinic to Open in Tehran




SMP Pharmacy Solutions Receives Eighth Inc. 5000 Recognition

Wed, 28 Sep 2016 15:07:37 EDT

Miami-Based Specialty Pharmacy Listed Among Top 20% of America's Fastest-Growing Private Companies




How Far Will You Go to Defeat Type 1 Diabetes

Wed, 28 Sep 2016 15:00:00 EDT

Canadians Ride Up to the Challenge; JDRF Revolution Ride




Medtronic, Phillips Healthcare Lead High Demand Billion Dollar U.S. Patient Monitoring Market

Wed, 28 Sep 2016 13:17:54 EDT

The U.S. Patient Monitoring Market Is Expected to Grow Over the Next Several Years to Reach Over $6 Billion by 2023




NCCN Congress to Explore Complex Issues in Treating Hematologic Malignancies

Wed, 28 Sep 2016 13:15:00 EDT

The NCCN 11th Annual Congress: Hematologic Malignancies(TM) Returns to New York City September 30 - October 1, 2016; Registration Is Still Open at NCCN.org/HEM




Commence Bio to Present at 2016 Cell & Gene Meeting on the Mesa

Wed, 28 Sep 2016 12:37:22 EDT

SPARKS, MD--(Marketwired - September 28, 2016) - Commence Bio, Inc., a biotechnology company focused on developing breakthrough immunotherapies using its proprietary STaRTT platform, announced today that Thomas Isett, CEO and Co-Founder, will present a company overview at the 2016 Cell & Gene Meeting on the Mesa [CGMOM]. Scheduled for October 5, at 2:45 PM (PDT), the presentation will highlight developments with the application of STaRT to create MSC1 and MSC2 cellular therapies for immuno-oncology and immune-mediated inflammatory diseases.




Cannabis Science Launches New Medicinal Product Line in Legal Dispensaries Within the State of California for Self-Medicating Patients

Wed, 28 Sep 2016 10:40:45 EDT

IRVINE, CA--(Marketwired - Sep 28, 2016) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce Cannabis Science launches new medicinal product lines for self-medicating patients via legal dispensaries and delivery within the State of California. The new CBIS medicinal product lines are being released based on patient usage data and general public opinion. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize target medicines for target ailments. These new medicinal products will be centerpieces for its new medicinal studies targeting its initial critical ailment list.




Medrio Rocks the House Down With Live Software Demonstrations at SCDM 2016

Wed, 28 Sep 2016 10:00:00 EDT

SAN FRANCISCO, CA--(Marketwired - September 28, 2016) - Medrio, a Software as a Service (SaaS) company providing electronic data capture (EDC) services to clinical trials, brought its Medrio Rocks World Tour to the Society for Clinical Data Management (SCDM) conference in San Diego from September 11 - 13. Hundreds of clinical data management professionals filled the Sheraton San Diego Hotel & Marina, including over 200 Medrio fans, who rushed to the front row at booth 201 to rock out to the company's chart-topping EDC.




New Features, Additional Keynote Speakers Will Round out 11th Annual Cardiometabolic Health Congress

Wed, 28 Sep 2016 09:39:41 EDT

BOSTON, MA--(Marketwired - September 28, 2016) - Continuing its dedication to translating late-breaking clinical research on cardiometabolic risk reduction into practical and targeted education, the Cardiometabolic Health Congress will hold its 11th Annual CMHC from October 5-8, 2016 at the Sheraton in Boston, MA.




Predicine Celebrates Grand Opening of Its R&D Facilities in Shanghai, China

Wed, 28 Sep 2016 09:37:02 EDT

HAYWARD, CA--(Marketwired - Sep 28, 2016) - Predicine celebrated the grand opening of its new R&D facilities in Shanghai, China, with a launch ceremony honoring the occasion on September 26, 2016. Invited dignitaries included government officials, collaborators and customers from leading hospitals, universities and pharmaceutical companies.




The Alliance for Regenerative Medicine Announces Fourth Annual 2016 European Advanced Therapies Investor Day

Wed, 28 Sep 2016 09:00:00 EDT

WASHINGTON, DC--(Marketwired - Sep 28, 2016) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, announced its annual European Advanced Therapies Investor Day will be held November 3, 2016 in London.




Defining Patient-Centricity Success Metrics & Demonstrating Initiative Value

Wed, 28 Sep 2016 08:31:00 EDT

20% of Pharmaceutical Companies Struggle Due to Increased Focus on Consumer Experience




mCig, Inc. CEO to Retire 50 Million Underlying Common Shares of Company Stock to the Company Treasury

Wed, 28 Sep 2016 07:00:00 EDT

HENDERSON, NV--(Marketwired - Sep 28, 2016) - mCig, Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis, hemp, and CBD markets, announced today its Chairman and CEO, Paul Rosenberg, is pleased to announce he has voluntarily returned 5 million Series A Preferred shares, representing 50 million underlying common stock to the company treasury. The process will be completed by September 30th, 2016.




Tissue Collection Standards Determine the Future of Precision Medicine, New Webinar Hosted by Xtalks

Wed, 28 Sep 2016 07:00:00 EDT

TORONTO, ON--(Marketwired - September 28, 2016) - Join industry expert Dr. Hartmut Juhl, Professor, Founder and CEO of Indivumed GmbH and IndivuTest GmbH (Hamburg), as he discusses how tissue collections standards will play a role in the future of precision medicine. There will be two live broadcasts on Tuesday, October 18, 2016 at 9am EDT (2pm BST/UK) and 1pm EDT.




Medivation Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016

Wed, 28 Sep 2016 06:00:00 EDT

SAN FRANCISCO, CA--(Marketwired - September 28, 2016) - Medivation, Inc. (NASDAQ: MDVN) today announced that new data from Company-sponsored and investigator-initiated clinical trials will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, being held October 7-11, in Copenhagen. Presentations include a pilot study of the company's investigational PARP inhibitor talazoparib in patients with BRCA-mutated breast cancer, and analyses of enzalutamide in the advanced prostate cancer setting, representing research advances in serious diseases for which there are limited options.




Astavita Brings AstaMed(R) MYO, Prescription Medical Food for Clinical Dietary Management of Sarcopenia, Into Symplmed DyrctAxess Technology(R)

Tue, 27 Sep 2016 15:48:35 EDT

New Patient Membership Program to Improve Access to Medications for Individuals Living With Sarcopenia




Whistler Medical Marijuana Corporation (WMMC), a Certified Organic Licensed Producer of Medical Cannabis, Today Announced the Release of Canada's First High Cannabigerol (CBG) Cannabis Oil

Tue, 27 Sep 2016 13:49:56 EDT

WHISTLER, BC--(Marketwired - September 27, 2016) - The release follows two years of research identifying the best medical phenotypes from the diverse seed bank at WMMC. The process identified a unique phenotype containing significant amounts of both THC and CBG at maturity which now forms the starting material for their High CBG oil.




Quidel Receives FDA Clearance for Its Solana(R) Influenza A+B Assay in Time for the Upcoming 2016-2017 Flu Season

Tue, 27 Sep 2016 13:14:18 EDT

SAN DIEGO, CA--(Marketwired - September 27, 2016) - Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Solana® Influenza A+B assay for the detection of nucleic acids isolated from nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection to aid in the diagnosis of Influenza A and B infections. The Solana® Influenza A+B Assay is intended for use only with the Solana® instrument.




Premier Biomedical Pain Management Solutions Announces Shipment of Initial Samples of Opioid-Free, 50-State Legal, CBD-Based Pain-Relieving Topical Patch

Tue, 27 Sep 2016 10:00:00 EDT

EL PASO, TX--(Marketwired - Sep 27, 2016) -  Premier Biomedical, Inc. (OTCQB: BIEI) announced today their newly created joint venture company, Premier Biomedical Pain Management Solutions, LLC (PBPMS) has manufactured and shipped initial design sample pain relieving topical patches for distribution to select VA hospital patients, military personnel, doctors, and professional sports figures. These patent-pending, opioid- and narcotic-free all-natural-ingredient topical pain relief patches consist of a proprietary mechanism for extended delivery of their cannabis-based medical CBD pain relieving compound, which is legal in all 50 states.




Prolacta Bioscience(R) Announces Formation of Scientific Advisory Board to Lead Further Breakthroughs in Advancing the Science of Human Milk(R)

Tue, 27 Sep 2016 10:00:00 EDT

Inaugural Board Convened During the 4th Annual International Conference on Human Milk Science and Innovation




Johnson & Wales University Announces The Food Innovation Nexus: a Venture Towards Therapeutic Breakthroughs in Healthy Food and Medicine

Tue, 27 Sep 2016 09:06:00 EDT

PROVIDENCE, RI--(Marketwired - September 27, 2016) - Johnson & Wales University (JWU), a world-renowned culinary educator, is no stranger to food innovation. Today it is announcing its newest venture to spur therapeutic breakthroughs at the intersection of healthy food and medicine: The Food Innovation Nexus (FIX).




Pega Launches Industry's First End-to-End Automation Platform to Intelligently Optimize How Work Gets Done With Robotic Automation, BPM, and CRM

Tue, 27 Sep 2016 09:00:00 EDT

Pega Robotic Automation Now Unified With Pega BPM Platform and CRM Applications to Automate Tasks, Streamline Processes, and Enhance Customer Engagement




The Alliance for Regenerative Medicine Submits Comments in Response to the European Commission's Draft Guidelines on Good Manufacturing Practice for Advanced Therapy Medicine Products

Tue, 27 Sep 2016 09:00:00 EDT

BRUSSELS, BELGIUM and WASHINGTON, DC--(Marketwired - Sep 27, 2016) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, has submitted written comments in response to the European Commission (EC)-issued targeted stakeholder consultation document on the draft Guidelines on Good Manufacturing Practice for Advanced Therapy Medicine Products (ATMP).




RepliCel Announces Debt Settlement

Tue, 27 Sep 2016 09:00:00 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 27, 2016) - RepliCel Life Sciences Inc. (OTCQB:REPCD)(TSX VENTURE:RP)(FRANKFURT:P6P2) ("RepliCel" or the "Company"), a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce its intention to settle debt (the "Debt Settlement") in the aggregate amount of $374,071.63 owed by the Company to certain creditors by the issuance of 719,368 units (each, a "Unit"). Each Unit consists of one common share of the Company (each, a "Share") and one share purchase warrant (each, a "Warrant"), with each Warrant entitling the holder to purchase one additional Share for a period of two years at a price of $1.10 per Share.




BioNap Consulting's Jason Napodano Issues an Update on BriaCell Therapeutics Corp.

Tue, 27 Sep 2016 08:30:00 EDT

BERKELEY, CA and VANCOUVER, BC--(Marketwired - September 27, 2016) - BioNap Consulting, Inc.'s Senior Equity Analyst, Jason Napodano, CFA, issued an update outlining the meaningful progress of BriaCell Therapeutics Corp. (TSX VENTURE: BCT) (OTCQB: BCTXF) or BriaCell towards initiation of Phase I/IIa clinical testing of BriaVaxT, BriaCell's proprietary allogeneic whole tumor cell vaccine, in late-stage breast cancer patients in the fourth quarter of 2016.




American Cannabis Company Inc. Features SoHum Living Soil(TM) at Canadian Industry Event and Establishes 8 New Retail Accounts

Tue, 27 Sep 2016 08:30:00 EDT

DENVER, CO--(Marketwired - Sep 27, 2016) - American Cannabis Company, Inc. (OTCQB: AMMJ) (the "Company"), a full-service business-to-business consulting solutions provider, product manufacturer and seller of ancillary products to the cannabis industry, today announced that it was in attendance at a Canadian industry event featuring its SoHum Living SoilsT product and that it successfully established eight new retail sales accounts for the SoHumT brand. ACC expects to begin filling these retail pre-orders in the spring of 2017.




Breathtec Biomedical Engages DTG Partners to Advance Product Commercialization

Tue, 27 Sep 2016 08:30:00 EDT

Medical Product Development Consultancy Aims to Deliver Proven, Time-Efficient and Cost-Effective Expertise




North Springs Resources Corp. Announces the Unveiling of Major Business Announcement to Shareholders Before Oct 1st 2016

Tue, 27 Sep 2016 08:30:00 EDT

RIVERVIEW, FL--(Marketwired - Sep 27, 2016) - North Springs Resources Corp. (OTC PINK: NSRS) is pleased to announce that the Company has worked closely with the Company's strategic partner and plans to issue an update to shareholders on or before Oct 1st 2016 regarding a contractual agreement that is expected to have a substantial and beneficial impact on the Company and its shareholders.




Top 5 Factors Pharma Companies Consider When Compensating Clinical Investigators

Tue, 27 Sep 2016 08:19:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - September 27, 2016) - The most important factor to determining clinical investigator compensation is the physician's therapeutic specialty, according to a report published by pharmaceutical competitive intelligence firm Cutting Edge Information.




Adgero Biopharmaceuticals to Present at the Fifth Annual OktoberINVESTfest, US - Bavaria, Germany Investors Conference in New York

Tue, 27 Sep 2016 07:30:00 EDT

German, US Business Leaders and Investors to Convene September 28th at NY Academy of Sciences




Blood Cancer Drugs Leading Growth in Global Hematology Market, Reports BCC Research

Tue, 27 Sep 2016 05:00:00 EDT

WELLESLEY, MA--(Marketwired - September 27, 2016) - Incidence and mortality rates for most cancers are increasing in emerging countries, mostly due to the adoption of unhealthy Western lifestyles such as smoking, physical inactivity, and diet. BCC Research reveals in its new report that the hematological cancer drug sector is leading growth in the global market for hematology drugs and diagnostics.




RepliCel Provides Update on Shiseido License and Co-Development for RCH-01

Mon, 26 Sep 2016 17:47:34 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 26, 2016) - RepliCel Life Sciences Inc. (OTCQB:REPCD)(TSX VENTURE:RP)(FRANKFURT:P6P2) ("RepliCel" or the "Company"), a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to provide an update on the licensing and co-development of its RCH-01 product with Shiseido Company.




Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Mon, 26 Sep 2016 17:15:00 EDT

Novel 4-1BB/HER2 Bispecific Demonstrates Differentiation Over Conventional 4-1BB mAb and HER2 mAb Approaches




Biodel Announces 2016 Annual Meeting of Stockholders Set for October 24, 2016; Outlines Plan to Regain Compliance With Nasdaq Listing Requirements

Mon, 26 Sep 2016 16:30:00 EDT

DANBURY, CT--(Marketwired - September 26, 2016) - Biodel Inc. (NASDAQ: BIOD) today announced that its 2016 annual meeting of stockholders has been set for October 24, 2016. At that meeting, stockholders will vote on, among other things, matters necessary to complete Biodel's planned transaction with Albireo Limited pursuant to a previously announced share exchange agreement, including the issuance of shares of Biodel's common stock in the transaction and a proposed reverse stock split of Biodel's common stock at a ratio of 1-for-30 shares.




Ogilvy CommonHealth Worldwide's Ritesh Patel to Deliver a Keynote Address at the Technology for Marketing 2016 Conference

Mon, 26 Sep 2016 13:51:52 EDT

PARSIPPANY, NJ--(Marketwired - Sep 26, 2016) - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP company (NASDAQ: WPPGY) (www.wpp.com), today announced Ritesh Patel, EVP, chief digital officer, has been selected as a keynote speaker at the 2016 Technology for Marketing event taking place on September 28 and 29 in Olympia London.




NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms

Mon, 26 Sep 2016 12:03:22 EDT

New NCCN Guidelines for Myeloproliferative Neoplasms Focus on the Treatment of Myelofibrosis, a Rare Bone Marrow Cancer; the New Recommendations Are the Most Comprehensive Treatment Guidance Available to U.S. Clinicians Today




MasterControl Provides Industry Insight on Leveraging Big Data in Post-Market Surveillance at Medical Product and Outsourcing's 2016 Summit

Mon, 26 Sep 2016 11:57:37 EDT

AUSTIN, TX--(Marketwired - Sep 26, 2016) -  MasterControl, a leading global provider of enterprise quality management systems (EQMS) and quality and compliance consulting services, will offer valuable information for the medical device industry at Medical Product and Outsourcing's Summit Oct. 5-6 in Austin, Texas.




Mr. Raymond C. Dabney, CBIS CEO, Accepts Invitation to Speak at Harvard Medical School

Mon, 26 Sep 2016 10:18:41 EDT

WASHINGTON, DC--(Marketwired - Sep 26, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announces that its President, Chief Executive Officer, and Co-Founder, Mr. Raymond C. Dabney, has accepted an invitation to speak at Harvard Medical School this November. Mr. Dabney will speak at the Dana Farber/Harvard Cancer Center (DF/HCC), one of the largest cancer research centers in the world with more than 1,100 cancer researchers and over $600 million in cancer research funding. He will discuss CBIS' drug development initiatives targeting a variety of cancers, within the context of a number of other disorders, such as autism spectrum disorders, asthma, as well as pain management.




Sermonix Pharmaceuticals' Exploratory Analysis on Orgasm Frequency With SERMs Is Named Featured Poster for 2016 North American Menopause Society Annual Meeting

Mon, 26 Sep 2016 09:55:00 EDT

Sermonix Also to Present Poster on Physicians' Perceptions of SERMs in Menopausal Health




TraceLink to Discuss Global Serialisation Strategies at CPhI Worldwide

Mon, 26 Sep 2016 09:00:00 EDT

NORTH READING, MA--(Marketwired - Sep 26, 2016) -  TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, will be addressing delegates at CPhI Worldwide, the annual pharmaceutical congress taking place October 4 - 6, in Barcelona, Spain. TraceLink will be partnering with its customer, Sharp Packaging Services, to display its proven Life Sciences Cloud solution in the Sharp CPhI booth in Hall 3, Stand L56.




Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day

Mon, 26 Sep 2016 08:30:00 EDT

LEXINGTON, MA--(Marketwired - Sep 26, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)




DiamiR Provides Update on Its Patent Portfolio, Launches New Website

Mon, 26 Sep 2016 08:02:00 EDT

MONMOUTH JUNCTION, NJ--(Marketwired - September 26, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, reported today that the following new patents have been issued or allowed between April and September 2016:

"Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases" in Europe (issued in the United States in February 2014);




ORYZON Closes EUR 5.3 Million (6 M USD) in additional Debt Financing

Mon, 26 Sep 2016 08:00:00 EDT

With These Funds the Company Completes Its Global Funding of EUR 32 Million (36 Million USD)




Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

Mon, 26 Sep 2016 07:03:00 EDT

NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 26, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO)

  • Phase 1 clinical trial in five patients demonstrated EB-101 (gene corrected skin grafts) was well tolerated and demonstrated promising clinical efficacy in patients for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)
  • Significant improvements in wound healing and gene expression observed up to 12 months post-treatment

Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapies for life-threatening rare diseases, announced that the first patient was enrolled in the Phase 2 portion of the clinical trial for EB-101 (gene-corrected skin grafts). EB-101 is the Company's lead gene therapy program for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of epidermolysis bullosa (EB).




Upcoming Webinar to Examine Market Access Hurdles for Cell and Gene Therapies

Mon, 26 Sep 2016 07:00:00 EDT

TORONTO, ON--(Marketwired - September 26, 2016) - The presentation will focus on managing evidence including market access and reimbursement challenges around cell and gene therapies to enhance market adoption.




If Canada Adopts New Zealand's Prescription Drug Policies There Will Be Fewer Treatment Options and Poorer Health Outcomes for Patients: Canadian Health Policy Institute (CHPI) Study

Mon, 26 Sep 2016 06:00:00 EDT

TORONTO, ON--(Marketwired - September 26, 2016) - The federal House of Commons Standing Committee on Health has been holding ongoing hearings about the Development of a National Pharmacare Program in Canada. Advocates of national pharmacare have told the Committee that Canada should adopt a New Zealand-style prescription drug system. However, a new study suggests that importing New Zealand-styled pharmacare policies into our country would lead to fewer drug treatment options and poorer health outcomes for Canadian patients.